Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.T-Ray Science, TeraView Enter Into Sub-Licensing Agreement
As per the terms of the sub-licensing agreement, T-Ray Science is expected to collect royalties on the sales of this product and any other products that utilise CW
As per the terms of the sub-licensing agreement, T-Ray Science is expected to collect royalties on the sales of this product and any other products that utilise CW
Silence Therapeutics said that the patent is issued for the methods of producing double stranded (RNAi) agents having decreased off-target silencing activity through certain structural modifications. Apart from
As per the terms of the agreement, NINDS is expected to fully fund and carry out a double-blind, cross-over, placebo-controlled, Phase II clinical trial in patients with epilepsy,
Azelastine ophthalmic solution is a prescription medication used for relieving itching caused by eye allergies. This medication comes in the form of an eye drop that is generally
Tamir said that Onconase is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies
The EC approval for Orencia is for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to previous therapy with
AMRI is expected to screen Aquapharm’s library against Gram-negative and Gram-positive bacteria and an undisclosed anti-inflammatory target. Additionally it is also expected to isolate and elucidate the structures
Promega and SignalChem Pharma said that the solution is a combination of an expanding series of Kinase Enzyme Systems and Promega’s new, bioluminescent ADP-Glo Kinase Assay, which is
Millipore claimed that ProRes-S media offers biopharmaceutical manufacturers flexibility and increased throughput in a smaller manufacturing footprint. Millipore has developed ProRes-S media, jointly with The Dow Chemical Company.
Alnylam Pharma said that the study is expected to enroll approximately 28 ATTR patients. Further, the trial is designed to provide preliminary data on human proof of concept